Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Instagram Outage Disrupts Thousands of U.S. Users 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
